Y-mAbs Therapeutics (Y-mAbs Therapeutics) Gross Margin % : 91.27% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Y-mAbs Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Y-mAbs Therapeutics's Gross Profit for the three months ended in Dec. 2023 was $21.32 Mil. Y-mAbs Therapeutics's Revenue for the three months ended in Dec. 2023 was $23.36 Mil. Therefore, Y-mAbs Therapeutics's Gross Margin % for the quarter that ended in Dec. 2023 was 91.27%.

The historical rank and industry rank for Y-mAbs Therapeutics's Gross Margin % or its related term are showing as below:

YMAB' s Gross Margin % Range Over the Past 10 Years
Min: 86.54 Med: 88.9 Max: 92.8
Current: 86.54

During the past 8 years, the highest Gross Margin % of Y-mAbs Therapeutics was 92.80%. The lowest was 86.54%. And the median was 88.90%.

YMAB's Gross Margin % is ranked better than
81.5% of 735 companies
in the Biotechnology industry
Industry Median: 59.4 vs YMAB: 86.54

Y-mAbs Therapeutics had a gross margin of 91.27% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Y-mAbs Therapeutics was 0.00% per year.

Y-mAbs Therapeutics Gross Margin % Historical Data

The historical data trend for Y-mAbs Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-mAbs Therapeutics Gross Margin % Chart

Y-mAbs Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

89.38

92.80

88.41

86.54

Y-mAbs Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															93.58	89.71	77.60	87.07	91.27

Competitive Comparison of Y-mAbs Therapeutics's Gross Margin %

For the Biotechnology subindustry, Y-mAbs Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Y-mAbs Therapeutics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Y-mAbs Therapeutics's Gross Margin % falls into.

Y-mAbs Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Y-mAbs Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	73.4	/	84.819
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(84.819 - 11.416)	/	84.819
	=	86.54 %

Y-mAbs Therapeutics's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	21.3	/	23.363
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(23.363 - 2.039)	/	23.363
	=	91.27 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Y-mAbs Therapeutics (NAS:YMAB) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Y-mAbs Therapeutics had a gross margin of 91.27% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Y-mAbs Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Y-mAbs Therapeutics (Y-mAbs Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-mAbs Therapeutics Inc (NAS:YMAB) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

230 Park Avenue, Suite 3350, New York, NY, USA, 10169

Website

https://www.ymabs.com

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. The vast majority of the Company's product sales are generated in the United States with additional sales outside the United States in China and Israel through sublicenses and distribution agreements.

Executives

Thomas Gad	director, officer: President and Chairman	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Biotech Aps Wg	10 percent owner	RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Johan Wedell-wedellsborg	director, 10 percent owner	RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Michael J Rossi	director, officer: President & CEO	230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Vignesh Rajah	officer: SVP and CMO	HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950
Bo Kruse	director, officer: EVP, CFO, Secy & Treas.	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Susan Laura Smith	officer: Senior Vice President, CCO	5 OVERLOOK CT, LAMBERTVILLE NJ 08530
David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Juan Moller San Pedro Claus	director, officer: Chief Executive Officer	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Mahiuddin Ahmed	officer: Sr. VP and CSO	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Philip Karl Herman	officer: Sr. VP and CCO	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Gregory S Raskin	director	C/O MEMORIAL SLOAN KETTERING CANCER CENT, 1275 YORK AVENUE, BOX 524, NEW YORK NY 10065
Gerard Ber	director	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169